[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100638454":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":30,"responsibleParty":44,"collaborators":20,"id":47,"slug":20,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":20,"eligibilityCriteria":51,"healthyVolunteers":48,"sex":52,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":20,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":20,"overallStatus":64,"whyStopped":20,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":74},{"fullName":5,"class":6},"Mayo Clinic","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Lisinopril","EXPERIMENTAL","Patients diagnosed with polycythemia will be treated with Lisinopril, 2.5 mg tablets",[13],"Drug: Lisinopril Tablets",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Lisinopril Tablets","Subjects will be treated with Lisinopril in three phases:\n\nPhase 1:\n\nBaseline-3 weeks: 2.5 mg dose\n\nPhase 2:\n\nWeeks 4 - 7: 5 mg dose (2 x 2.5mg tablets)\n\nPhase 3:\n\nWeeks 8-12: 10 mg dose (4 x 2.5 mg tablets)",[9],null,[22],{"name":23,"affiliation":5,"role":24},"Michael Joyner, MD","PRINCIPAL_INVESTIGATOR",[26],{"name":27,"role":28,"phone":29,"phoneExt":20,"email":20},"Nancy Meyer","CONTACT","507-255-0913",[31],{"facility":32,"status":20,"city":33,"state":34,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":20},"St. Mary's Hospital","Rochester","Minnesota","55902","United States","US",{"type":39,"coordinates":40},"Point",[41,42],-92.4699,44.02163,{"lat":42,"lon":41},{"type":24,"investigatorFullName":45,"investigatorTitle":46,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"Michael J. Joyner, M.D.","Principal Investigator","100638454",false,"NCT07594535","The Effect Of Lisinopril On Polycythemia","Inclusion Criteria:\n\n* Hemoglobin in Men: \\>16.5 g\u002FdL (10.3 mmol\u002FL).\n* Hemoglobin in Women \\>16.0 g\u002FdL (10.0 mmol\u002FL).\n* BMI 18-40 kg\u002Fm2.\n\nExclusion Criteria:\n\n* Positive JAK2 gene linked to Polycythemia Vera.\n* Current smoker or previous heavy smoker (\\>15 pack years) who quit less than 12 months prior to enrollment.\n* Resting SpO₂ ≤ 94% on room air.\n* Current or recent (within the past 6 months) use of testosterone or androgen supplementation.\n* Any confounding respiratory or renal disease, including diagnosed or suspected sleep apnea, or stage 3 and up of chronic kidney disease.\n* Any confounding hematologic disease that may alter hemoglobin level.\n* Currently treated with ACE inhibitors.\n* Currently treated with potassium-sparing diuretics.\n* Currently on SGLT2 or use within 4 weeks prior to screening.\n* Baseline systolic blood pressure ≤90 mmHg.\n* Baseline systolic blood pressure \\>160 mmHg or diastolic blood pressure \\>100 mmHg.\n* Occupational exposure associated with chronically elevated COHb (auto repair, etc.).\n* History of anaphylaxis or angioedema.\n* Pregnant or breastfeeding.","ALL","18 Years","80 Years",{"count":56,"type":57},30,"ESTIMATED","INTERVENTIONAL",[60],"PHASE4","The purpose of this study is to evaluate the effect of the (angiotensin-converting enzyme) ACE inhibitor lisinopril on hemoglobin, hematocrit, and erythropoietin levels in patients with secondary polycythemia due to high-oxygen-affinity hemoglobin variants, oxygen-sensing pathway mutations, or other unexplained and potentially irreversible forms of erythrocytosis. This study aims to determine whether ACE inhibition can effectively reduce excessive erythrocytosis by modulating erythropoietin production.",[63],"Polycythemia","NOT_YET_RECRUITING","2026-05-13",{"date":67,"type":68},"2026-05-18","ACTUAL",{"date":70,"type":57},"2026-07-01",{"date":72,"type":57},"2029-07-01",{"name":5,"class":6},1]